agilon health, inc.

agilon health, inc. (AGL) Stock Analysis

$90.990

-0.728 (-0.80%)At close

Loading chart…
High
93.855
Open
91.170
VWAP
91.18
Volume
208.69K
Mkt Cap
2.71B
Low
88.680
Amount
19.03M
EV/EBITDA, TTM
12.99

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.

AI analysis of agilon health, inc. (AGL)

Buy

Agilon Health is a good buy right now due to its recent positive earnings report showing a Q2 revenue of $1.49 billion, exceeding expectations, and an adjusted EPS of $2.15, far above the estimate of $0.27. The stock is currently priced at $85.12, with a significant upside potential as analysts have set a price target of $125, representing a potential upside of 47%.

Valuation Metrics

The current forward P/E ratio for agilon health, inc. (AGL) is 178.57, compared to its 5-year average forward P/E of 28.43.

Forward P/E

Fair
5Y Average P/E
28.43
Current P/E
178.57
Overvalued
321.31
Undervalued
-264.44

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
149.05
Current EV/EBITDA
12.99
Overvalued
588.25
Undervalued
-290.15

Forward P/S

Fair
5Y Average P/S
1.16
Current P/S
0.24
Overvalued
2.38
Undervalued
-0.07

Alphio AI Price Scenarios for AGL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AGL

$3.37

Scenario price

B

Base

Base · 50%AGL

$3.18

Scenario price

B

Bear

Bear · 25%AGL

$2.51

Scenario price

Whales holding AGL

N

Nt-Comnwlth Super Corp

+ HoldingAGLCSL

-0.81%

3M Return

D

Durable Capital Partners, LP

+ HoldingAGL

-3.41%

3M Return

I

IOOF Investment Management Limited

+ HoldingAGL

-3.64%

3M Return

R

Rock Springs Capital Management LP

+ HoldingAGL

-9.50%

3M Return

Events Timeline

2026-09-30 (ET)

09:30:00

Agilon Health Expands Partnership with The Jackson Clinic

2026-09-23 (ET)

09:30:00

Agilon Health Expands Partnership with Springfield Clinic

2026-09-10 (ET)

09:30:00

Agilon Health Expands Partnership with Family Practice Center

2026-08-05 (ET)

17:00:00

agilon health Q2 Revenue $1.49B, Exceeds Expectations

17:00:00

Sees Q3 Adjusted EBITDA at -$5M

News

AGL FAQ — answered by Alphio AI

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Agilon Health is a good buy right now due to its recent positive earnings report showing a Q2 revenue of $1.49 billion, exceeding expectations, and an adjusted EPS of $2.15, far above the estimate of $0.27. The stock is currently priced at $85.12, with a significant upside potential as analysts have set a price target of $125, representing a potential upside of 47%.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading